InflaRx N.V. is a clinical-stage biopharmaceutical company that specializes in discovering and developing inhibitors using C5a technology. The company's lead product candidate, vilobelimab, is a novel anti-C5a monoclonal antibody for the treatment of various autoimmune and inflammatory diseases. InflaRx N.V. also develops other drug candidates for chronic inflammatory and autoimmune diseases.